A Phase 4 interventional study of Enteric-coated mycophenolate sodium (Myfortic) and Cyclosporine (Neoral) in Kidney Transplantation, sponsored by Novartis. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-03-01.
Sponsored by Novartis · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine if an initial intensified enteric-coated mycophenolate sodium (Myfortic) dosing regimen administered during the first six weeks post renal transplantation provides improved efficacy, with a similar safety profile, compared to a standard regimen of Myfortic.
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In patients randomized to the intensified Myfortic dosing regimen, the initial dose was 2-fold of the labeled dose (i.e. 2880 mg/day). The dosage was reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
Drug: Enteric-coated mycophenolate sodium (Myfortic) · Drug: Cyclosporine (Neoral) · Drug: Prednisone
In patients randomized to the standard Myfortic dosing regimen, the initial dose of 1440 mg/day had to be maintained throughout the whole study.
Drug: Enteric-coated mycophenolate sodium (Myfortic) · Drug: Cyclosporine (Neoral) · Drug: Prednisone
1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
Number of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death
To evaluate therapeutic benefit by comparing the efficacy defined as the number of participants with treatment failure (biopsy-proven acute rejection \[BPAR\], graft loss \[GFL\] or death) at 6 months post-transplant. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.)
Time frame: 6 months
Comparison of Overall Treatment Failure at Days 21 and 84 Post-transplantation Assessed by Biopsy Proven Acute Rejection (BPAR), GFL, and Death
The overall treatment differences of the number of participants with at least one occurrence of the composite event BPAR, GFL or death at study days 21 and 84 post-transplantation. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.)
Time frame: 21 and 84 days
Renal Function Assessed by Glomerular Filtration Rate (GFR)at Each Visit
The Modification of Diet in Renal Disease (MDRD) formula was used to calculate the GFR. Serum creatinine levels, age, sex and race were used to estimate the GFR levels in mL/min/1.73m\^2.
Time frame: at 21 days, 84 days and 180 days
Renal Function Assessed by Serum Creatinine at Each Visits
Time frame: at 21 days, 84 days and 180 days
| Milestone | Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen | Standard Mycophenolate Sodium (Myfortic) Dosing Regimen |
|---|---|---|
| Started | 155 | 158 |
| Completed | 141 | 148 |
| Not completed | 14 | 10 |
| Withdrew: Withdrawal by subject | 7 | 3 |
| Withdrew: Administrative problem | 4 | 4 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Death | 2 | 1 |
To evaluate therapeutic benefit by comparing the efficacy defined as the number of participants with treatment failure (biopsy-proven acute rejection \[BPAR\], graft loss \[GFL\] or death) at 6 months post-transplant. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.)
| number of participants | Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen | Standard Mycophenolate Sodium (Myfortic) Dosing Regimen |
|---|---|---|
| Number of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death | 33 | 36 |
The overall treatment differences of the number of participants with at least one occurrence of the composite event BPAR, GFL or death at study days 21 and 84 post-transplantation. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.)
| number of participants | Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen | Standard Mycophenolate Sodium (Myfortic) Dosing Regimen |
|---|---|---|
| Day 21 | 20 | 21 |
| Day 84 | 33 | 34 |
The overall treatment differences of the number of participants with at least one occurrence of the composite event BPAR, GFL or death at study days 21 and 84 post-transplantation. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.)
| number of participants | Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen | Standard Mycophenolate Sodium (Myfortic) Dosing Regimen |
|---|---|---|
| Day 21 | 14 | 20 |
| Day 84 | 26 | 33 |
The Modification of Diet in Renal Disease (MDRD) formula was used to calculate the GFR. Serum creatinine levels, age, sex and race were used to estimate the GFR levels in mL/min/1.73m\^2.
| (mL/min/1.73m^2) | Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen | Standard Mycophenolate Sodium (Myfortic) Dosing Regimen |
|---|---|---|
| At 21 days | 47.3 ± 20.05 | 46.8 ± 21.00 |
| At 84 days | 52.1 ± 19.80 | 51.8 ± 20.21 |
| At 180 days | 53.5 ± 21.05 | 51.3 ± 25.14 |
Results for this outcome have not been posted.
To evaluate therapeutic benefit by comparing the efficacy defined as the number of participants with treatment failure (biopsy-proven acute rejection \[BPAR\], graft loss \[GFL\] or death) at 6 months post-transplant. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.)
| number of participants | Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen | Standard Mycophenolate Sodium (Myfortic) Dosing Regimen |
|---|---|---|
| Number of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death | 26 | 35 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen | — | 74/150 (49.3%) | 143/150 (95.3%) |
| Standard Mycophenolate Sodium (Myfortic) Dosing Regimen | — | 68/154 (44.2%) | 145/154 (94.2%) |
| Event | Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen | Standard Mycophenolate Sodium (Myfortic) Dosing Regimen |
|---|---|---|
| Cytomegalovirus infectionInfections and infestations | 10/150 | 16/154 |
| Urinary tract infectionInfections and infestations | 9/150 | 11/154 |
| Kidney transplant rejectionImmune system disorders | 1/150 | 7/154 |
| Complications of transplanted kidneyInjury, poisoning and procedural complications | 6/150 | 1/154 |
| LymphoceleVascular disorders | 1/150 | 6/154 |
| Blood creatinine increasedInvestigations | 5/150 | 5/154 |
| LeukopeniaBlood and lymphatic system disorders | 4/150 | 0/154 |
| Renal graft lossInjury, poisoning and procedural complications | 2/150 | 4/154 |
| Atrial fibrillationCardiac disorders | 3/150 | 0/154 |
| Abdominal painGastrointestinal disorders | 3/150 | 1/154 |
| Event | Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen | Standard Mycophenolate Sodium (Myfortic) Dosing Regimen |
|---|---|---|
| ConstipationGastrointestinal disorders | 58/150 | 51/154 |
| HypertensionVascular disorders | 51/150 | 45/154 |
| Urinary tract infectionInfections and infestations | 46/150 | 38/154 |
| Oedema peripheralGeneral disorders | 42/150 | 46/154 |
| NauseaGastrointestinal disorders | 43/150 | 38/154 |
| DiarrhoeaGastrointestinal disorders | 40/150 | 27/154 |
| VomitingGastrointestinal disorders | 29/150 | 41/154 |
| AnaemiaBlood and lymphatic system disorders | 39/150 | 37/154 |
| Procedural painInjury, poisoning and procedural complications | 36/150 | 32/154 |
| HypocalcaemiaMetabolism and nutrition disorders | 12/150 | 27/154 |
| Age, Customized(participants) | Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen | Standard Mycophenolate Sodium (Myfortic) Dosing Regimen | Total |
|---|---|---|---|
| < 50 years | 100 | 102 | 202 |
| >=50 years | 55 | 56 | 111 |
| Sex: Female, Male(Participants) | Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen | Standard Mycophenolate Sodium (Myfortic) Dosing Regimen | Total |
|---|---|---|---|
| Female | 53 | 54 | 107 |
| Male | 102 | 104 | 206 |
The record gives a start of Dec 2006, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mycophenolic Acid · Cyclosporine